Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis ...
A wave of phase 3 candidates now in development are testing mechanisms that move beyond both paradigms, from 1-time gene therapies to angiopoietin pathway agonism and even sustained-release platforms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results